Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase EARLY_PHASE1 2Phase 2 2Phase 1/2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 5Breast 5Thoracic 3Other hematologic neoplasm 3Genitourinary 3CNS 3Tumor-Agnostic 2Sarcoma 2Plasma cell 2Lymphoid 2Gynecologic 2Dermatologic 2Myeloid 1Endocrine 1

Conditions

Multiple Myeloma 2Lymphoma 1

Interventions

Dexamethasone 373Lenalidomide 206Bortezomib 200Cyclophosphamide 178Melphalan 135Calcium Dobesilate 120daratumumab 107pomalidomide 74carfilzomib 74fludarabine phosphate 71Peripheral Blood Stem Cell Transplantation 66Thalidomide 57Filgrastim 57Mycophenolic Acid 56Busulfan 55Tacrolimus 48Granulocyte Colony-Stimulating Factor 47ixazomib 45fludarabine 45Whole-Body Irradiation 44dexamethasone acetate 36Cyclosporine 35isatuximab 34Etoposide 34Antilymphocyte Serum 32dexamethasone 21-phosphate 30elotuzumab 28auricularum 27Prednisone 27plerixafor 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Blood Specimen Collection × Plasma cell × Clear all
NCT04150692 2022-01-24

Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma

Washington University School of Medicine

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

NCT02260414 2017-05-11

METRO B

Centre Hospitalier Universitaire de Saint Etienne

Phase 2 Completed
19 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡